Saturday 17 October 2026
Export DYN’s income statement to Excel — free account
Dyne Therapeutics, Inc.
In the quarter to June 2026, EPS fell 11.3%, free cash flow fell 39.1% and total debt rose 116.0%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
14.25
1.04
−6.80%
Follow DYN
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
|
+8 more TTM periods Free account |
(60.66%) | (55.71%) | (58.89%) | (81.57%) | |
| (51.81%) | (47.52%) | (50.16%) | (60.29%) | ||
ROIC |
0.00% | (2,790.00%) | (607.10%) | (1,956.27%) | |
Return on Tangible Assets |
(55.01%) | (40.57%) | (45.47%) | (58.73%) | |
Free Cash Flow per Share |
(2.67) | (3.15) | (2.69) | (2.90) | |
Free Cash Flow |
(378.22) | (405.13) | (443.40) | (480.43) | |
Capital Expenditures |
(2.51) | (1.92) | (1.16) | (2.61) | |
| Other line items | |||||
Cash ROIC |
(23.90%) | (18.15%) | (22.25%) | (26.48%) | |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | |
Tax Rate |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Interest Coverage |
(60.75) | (55.86) | (45.32) | (36.05) | |
Operating CF/Net income |
0.89 | 0.90 | 0.98 | 0.92 | |
Depreciation/Fixed assets |
(0.01) | 0.01 | 0.03 | 0.04 | |
Capex/Depreciation |
8.23 | (8.97) | (1.91) | (2.92) | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
(2.65) | (3.14) | (2.68) | (2.89) | |
Capex per Share |
(0.02) | (0.01) | (0.01) | (0.02) | |
Capex to Sales |
0.00 | 0.00 | 0.00 | 0.00 |
Columns are period end dates